FDA approves Akeega, the first-and-only dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer – Janssen
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Akeega (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor… read more.
